Rational application of leflunomide in kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2014.04.002

Abstract

Abstract:

Leflunomide is a kind of anti-proliferation immunosuppressive agent, whose main mechanism is blocking the de novo synthesis of pyrimidines,and is an effective drug for the clinical treatment of various immune-mediated kidney diseases. Besides, in recent years, results of basic researches have disclosed that leflunomide has antiviral and podocyte-protective effects. Leflunomide has also proved to have special effects in the treatment of diabetic nephropathy, polyomavirus-associated nephropathy, and hepatitis B virus-associated glomerulonephritis. The reason that leflunomide is both safe and effective with affordable price has made leflunomide a preferred choice for combined application of immunosuppressants.

Key words: Leflunomide, Chronic kidney disease, Immunosuppressant

Hongli Lin, Hua Xie. Rational application of leflunomide in kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(04): 177-182.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.04.002

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I04/177

References 58

1	Li J, Yao HW, Jin Y, et al. Pharmacokinetics of leflunomide in Chinese healthy volunteers [J]. Acta Pharmacol Sin, 2002, 23(6):551-555.
2	Davis JP, Cain GA, Pitts WJ, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase [J]. Biochemistry, 1996, 35(4):1270-1273.
3	Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide [ J].Transplantation,1996,61(4):635-642.
4	Ringshausen I,Oelsner M,Bogner C, et al. The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells[J].Leukemia,2008,22(3):635-638.
5	Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice [J]. J Immunol, 1997, 159(1): 167-174.
6	Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases [J]. Immunopharmacology, 2000, 47(2-3):273-289.
7	González-Alvaro I, Ortiz AM, Domínguez-Jiménez C, et al.Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway [J]. Ann Rheum Dis,2009,68(10):1644-1650.
8	Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression [J]. J Immunol, 1999, 162(4):2095-2102.
9	Tang Y, Lou TQ, Wang C, et al. Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model [J]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2008, 20(5):283-285.
10	Farasati NA, Shapiro R,Vats A. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system [J].Transplantation,2005,79(1):116-117.
11	Tam LS, Li EK, Wong, CK, et al. Double-blind, randomized,placebo-controlled pilot study of leflunomide in systemic lupus erythematosus [J]. Lupus,2004,13(8):601-604.
12	Cui TG, Hou FF, Ni ZH, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial [J]. Zhonghua Nei Ke Za Zhi, 2005, 44(9):672-676.
13	Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study [J].Lupus,2008,17(7):638-644.
14	FY. The long-term outcomes of leflunomide in patients with lupus nephritis [J]. Lupus,2010,19(Abstract Supplement): CS12.5 &PO2.D.46.
15	Zhang FS, Nie YK, Jin XM, et al. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy [J].Rheumatol Int,2009,29(11):1331-1335.
16	Hu W, Zhang H, Sun H, et al. A clinical trial of maintenance treatment for lupus nephritis [J]. Chin J Nephrol Dial Transplant,2008,17(2):224-228.
17	来氟咪特治疗免疫性肾脏疾病的专家共识专家组.来氟咪特治疗免疫性肾脏疾病的专家共识[M]. 杭州: 中华医学会肾脏病学分会,2010:1-4.
18	缪世梅,达展云,王爱萍,等. 半量免疫抑制剂多靶点治疗狼疮肾炎的实验研究[J]. 中国风湿病学杂志, 2014, 18(2): 121-124.
19	Reinhold-Keller E. Diagnostics and therapy of antineutrophil cytoplasmic antibody (ANCA) associated vasculitides [J]. Curr Pharm Des,2012,18(29):4537-4541.
20	Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis [J]. Rheumatology (Oxford), 2014, [Epub ahead of print].
21	Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis[J]. Rheumatology,2007,46(7):1087-1091.
22	Hazlewood GS, Metzler C, Tomlinson GA, et al. Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis[J]. Joint Bone Spine,2014,81 (4):337-341.
23	KDIGO Work Group.Clinical Practice Guideline for Glomerulonephritis[J]. Kidney Int Suppl,2012,2(2):139-274.
24	张爱平,张磊,王艳侠,等. 来氟咪特治疗IgA 肾病64 例[J]. 中华肾脏病杂志,2004,20(3):176-176.
25	Liu XW, Li DM, Xu GS, et al. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome[J]. Int J Clin Pharmacol Ther,2010,48(8):509-513.
26	Rong L, Liu ZR. Effects of leflunomide combined with hormone therapy for refractory IgA nephropathy [J]. Nan Fang Yi Ke Da Xue Xue Bao,2007,27(6):893-894.
27	Lou T, Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy [J].Nephrology (Carlton),2006,11(2):113-116.
28	赵慧媛.来氟咪特联合激素治疗过敏性紫癜性肾炎的随机对照试验[J]. 中国现代药物应用,2011,5(23):1-2.
29	孙剑,张浩,刘纪实,等. 来氟咪特与霉酚酸酯治疗表现为肾病综合征的过敏紫癜性肾炎的疗效比较[J]. 中国中西医结合肾病杂志,2008,9(8):691-693.
30	张爱平,张磊,王艳侠,等. 来氟咪特治疗过敏性紫癜肾炎的临床研究[J]. 中国药物与临床,2004,4(5):350-352.
31	Chen CL, Hsu CY,Fang HC. Leflunomide in idiopathic membranous nephropathy: a new immunosuppressive with promising treatment potential [J]. Nephrology (Carlton),2014,19(1):1-2.
32	Yang S, Xie L, Xue W, et al. Leflunomide plus oral prednisone in treatment of idiopathic Membranous nephropathy: a retrospective clinical study of efficacy and safety [J]. Nephrology (Carlton),2013,18(9):615-622.
33	王成, 娄探奇, 余学清,等. 来氟咪特联合泼尼松治疗难治性原发性肾病综合征的随机对照试验[J]. 中国新药与临床杂志,2006,25(12):889-892.
34	汤力, 曹雪莹, 陈香美,等. 来氟咪特与霉酚酸酯治疗难治性肾病综合征的对照观察[J]. 北京医学,2004,26(5):297-299.
35	李国富, 刘婷, 包蓓艳. 来氟咪特与环磷酰胺治疗膜性肾病的疗效比较[J]. 中国中西医结合杂志,2011,12(10):872-874.
36	Xie G, Xu J, Ye C, et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults [J]. PloS One,2012,7(9): e44330.
37	Sun GD, Xu ZG,Luo P,et al. The clinical efficacy of tacrolimus in the treatment of idiopathic membranous nephropathy [J]. Chin J Gerontol,2008,28:469-471.
38	Chai WX, Yu WM, Li RS, et al. Effects of leflunomide on high glucose-induced podocyte cytoskeleton and its mechanism [J].Zhonghua Yi Xue Za Zhi,2013,93(10):780-784.
39	Zhao X, Yu WM, Li RS, et al. Effects of leflunomide on podocytes exposed to high glucose condition and its mechanism [J]. Zhonghua Yi Xue Za Zhi,2013,93(24):1911-1914.
40	Yuan YC, Yu WM, Li RS, et al. Inhibition of leflunomide active metabolite A771726 on high glucose-induced podocyte apoptosis[J]. Zhonghua Yi Xue Za Zhi,2011,91(10):703-706.
41	Yu WM, Wang H, Ren XJ, et al. Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats [J]. Nephrology (Carlton),2012,17(4):380-389.
42	王维平, 何萍, 姜璐. 来氟咪特联合缬沙坦及胰激肽原酶治疗糖尿病肾病的疗效观察[J]. 中国中西医结合肾病杂志, 2014,15(3):236-238.
43	付宇, 王丹, 石鹏, 等. 来氟咪特治疗糖尿病肾病大量蛋白尿20 例临床分析[J].临床内科杂志,2007,24(7):470-471.
44	Kim H, Yang WS, Han DJ, et al. Clinical courses of renal transplant recipients with high BK viremia [J]. Transplant Proc,2013,45(8):2975-2979.
45	Teschner S, Gerke P, Geyer M, et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection [J]. Transplant Proc,2009,41(6):2533-2538.
46	Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy [J]. N Engl J Med, 2005, 352(11):1157-1158.
47	Zaman RA, Ettenger RB, Cheam H, et al. A novel treatment regimen for BK viremia [J]. Transplantation, 2014, [Epub ahead of print].
48	杨玉贵. 恩替卡韦联合来氟咪特治疗乙肝病毒相关性肾炎的疗效[J]. 中国医学工程,2012,20(10):67.
49	夏德全,蔡淑芳,杨焕荣,等. 乙肝病毒相关性肾炎临床分析及拉米夫定联合来氟咪特、泼尼松干预作用[J]. 中国医学创新,2009,6(9):6-8.
50	向慧,孙剑. 来氟咪特与霉酚酸酯治疗乙肝病毒相关性肾炎的疗效比较[J].临床医学工程,2011,18(2):213-215.
51	Beaman JM,Hackett LP,Luxton G,et al. Effect of hemodialysis on leflunomide plasma concentrations[J]. Ann Pharmacother, 2002,36(1):75-77.
52	Iwamoto M, Homma S, Asano Y, et al. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis[J]. Scand J Rheumatol,2005,34(5):410-411.
53	Raj R, Nugent K. Leflunomide-induced interstitial lung disease (a systematic review) [J]. Sarcoidosis Vasc Diffuse Lung Dis, 2013,30(3):167-176.
54	Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis:a systematic literature review [J]. Semin Arthritis Rheum, 2014,43(5):613-626.
55	Inokuma S. Leflunomide-induced interstitial pneumonitis might be a representative of disease-Modifying anti-rheumatic drug-induced lung injury [J]. Expert Opin Drug Saf,2011,10(4):603-611.
56	Metzler C, Arlt AC, Gross WL, et al. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide[J]. Ann Rheum Dis,2005,64(12):1798-1800.
57	Santiago T, Rovisco J, Silva J, et al. Peripheral neuropathy and leflunomide [J]. Acta Reumatol Port,2011,36(3):313-314.
58	赵伟,张江林,黄烽. 来氟米特所致周围神经病变的临床特点及防治[J].药物不良反应杂志,2011,13(4):228-231.

[1]	Xiaoqing Tang, Ping He, You Yang, Xia Luo, Juying Zhang, Xin Yang, Jinhong Yu. Correlation of sound touch elastography combined with pulsed wave Doppler ultrasound imaging parameters with stage of early chronic kidney disease and their clinical significance [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 491-499.
[2]	Mingxing Guo, Ye Xu, Wanyi Xu, Ying Zhao, Ranjia Liu, Chen Pan, Xiangli Cui. Analysis of immunosuppressive drugs used in outpatient patients after kidney transplantation at 105 hospitals in China from 2017 to 2022 [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(02): 104-109.
[3]	Shuxun Ling, Yue Tu, Siyi Liu. Visualization analysis on knowledge map of mesenchymal stem cells in the research field of chronic kidney disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 73-82.
[4]	Zhihong Wei, Jianyong Liu, Xiaoya Wu, Fang Yang, Lizhi Lyu, Yi Jiang, Qiucheng Cai. Diagnosis and treatment of acute graft-versus-host disease after liver transplantation （report of four cases） [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 846-851.
[5]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association. Clinical practice guidelines for kidney injury management of liver transplant recipients in China(2023 edition) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 276-288.
[6]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[7]	Junnan Guo, Hui Lin, Yilin Ren, Xi Qiao. Progress of research on the role of amino acid metabolism disturbance in the transition from AKI to CKD [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 283-287.
[8]	Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.
[9]	Xiaolong Wang, Jie Wu, Shuwei Duan, Chaohui Wang, Na Pan, Yuanyuan Bai, Hangtian Li, Guangyan Cai. Effect of different levels of physical activity on the prognosis of patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 121-128.
[10]	Yinan Zhang, Guozhen Zhu. Research progress on the transition from acute kidney injury to chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 106-112.
[11]	Yansheng Wu, Xianwen Zhang, Lin Wang. Research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 101-105.
[12]	Jinyi Zhang, Yuehong Li. Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 97-100.
[13]	Wuhao Xiao, Kanghan Liu. Research progress on the treatment of osteoporosis in patients with advanced chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 92-96.
[14]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.
[15]	Heqing Ye, Jie Li, Yuyuan Zhang, Luqi Hu, Bailu Wu, Xin Li, Shuwen Ye, Yifan Li, Yue Gao, Pengchao Zhan, Peijie Lv, Zhen Li. Efficacy of chemoembolization with drug-eluting bead combined with Donafenib and PD-1 in the treatment of advanced large liver cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(03): 212-216.

Please choose a citation manager

Content to export